...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Seminars in cancer biology >CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation.
【24h】

CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation.

机译：人类造血细胞移植中的CD4 + CD25 +调节性T细胞。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Naturally occurring CD4+CD25+ regulatory T cells (T(reg)) are differentiated T lymphocytes actively involved in the control of peripheral immunity. Over the past few years, a number of animal studies have demonstrated the critical role of these cells in the outcome of allogeneic hematopoietic stem cell transplantation (HCT). In these models, T(reg) can exert a potent suppressive effect on immune effector cells reactive to host antigens and prevent graft versus host disease (GVHD) while preserving the graft-versus-leukemia effect (GVL). The present review summarizes current knowledge on the role of T(reg) populations in humans following allogeneic HCT. Recent investigations focusing on T(reg) in transplant patients have generated conflicting results mostly due to the use of different parameters to assess T(reg). Nonetheless, these studies suggested that an imbalance between T(reg) and effector cells during immune reconstitution can substantially impair regulatory mechanisms and contributes to the development of GVHD. Building on these studies, a number of therapeutic strategies are being developed to positively modulate T(reg) pools in vivo and prevent or even correct GVHD. Conversely, clinical interventions can also be envisaged to decrease T(reg) activity in vivo and enhance the GVL effect. These potential strategies are discussed herein. Coming years will undoubtedly yield additional knowledge on how to use T(reg) subsets in vivo and successfully control and modulate immune responses in patients post-HCT.
机译：天然存在的CD4 + CD25 +调节性T细胞（T（reg））是分化的T淋巴细胞，积极参与外周免疫的控制。在过去的几年中，许多动物研究证明了这些细胞在同种异体造血干细胞移植（HCT）结果中的关键作用。在这些模型中，T（reg）可以对与宿主抗原反应的免疫效应细胞发挥有效的抑制作用，并防止移植物抗宿主病（GVHD），同时保留移植物抗白血病作用（GVL）。本综述总结了异基因HCT后T（reg）人群在人类中的作用的当前知识。最近针对移植患者中T（reg）的研究产生了矛盾的结果，这主要是由于使用了不同的参数来评估T（reg）。尽管如此，这些研究表明，免疫重建过程中T（reg）与效应细胞之间的失衡会大大削弱调节机制，并促进GVHD的发展。在这些研究的基础上，正在开发许多治疗策略，以在体内积极调节T（reg）库并预防甚至纠正GVHD。相反，也可以设想临床干预措施以降低体内T（reg）活性并增强GVL效应。本文讨论了这些潜在策略。无疑，未来几年将产生有关如何在体内使用T（reg）亚型以及成功控制和调节HCT后患者免疫应答的其他知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号